NCT05061537 · OUTCOME

Part 2: Overall Survival

Study of PF-07263689 in Participants With Selected Advanced Solid Tumors · Source last updated 2024-04-12

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: Not reported
Unit: Not reported
Interval / dispersion: Not reported
Time frame: From start of study treatment to the date of death from any cause (up to 2 years)

What was measured

Overall survival was defined as the duration from the start of study treatment to the date of death from any cause.

Analysis population: Data was not collected as no participants were enrolled in Part 2 of the study due to study termination.

Participants were planned to receive PF-07263689 in combination with sasanlimab at the preliminary combination recommended Phase 2 dose from Part 1B.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Part 2: PF-07263689 + Sasanlimab	0

No numerical measurement classes were posted for this outcome. Missing is not zero.

Complete source fields

denoms

description

Overall survival was defined as the duration from the start of study treatment to the date of death from any cause.

groups

population Description

Data was not collected as no participants were enrolled in Part 2 of the study due to study termination.

reporting Status

POSTED

time Frame

From start of study treatment to the date of death from any cause (up to 2 years)

title

Part 2: Overall Survival

type

SECONDARY

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice